As a treating oncologist, you are the captain of the ship. When standard-of-care options are exhausted, referring a patient internationally for CAR-T, NK cell therapy, or a clinical trial in China can feel like handing over the wheel to a stranger. The unspoken fears are valid: Will the communication break down? Will the documentation be incomprehensible? Will I lose control of the patient's care pathway?

This guide dismantles those concerns. It outlines the Closed-Loop Referral Protocol, a standardized clinical workflow designed specifically for physician-to-physician collaboration. This is not a medical tourism brochure. It is a clinical operations manual that ensures your patient receives cutting-edge therapy in China while you remain fully integrated into their care team.

The 5-Phase Closed-Loop Protocol

1
DAYS 1-3

Pre-Referral & Patient Selection

Determine clinical viability and gather exact data for Chinese Tumor Board review

The Clinical Decision: When to Refer

Refer when the patient has relapsed/refractory disease, has exhausted local standard-of-care, and has an ECOG Performance Status of 0-2 (or highly selected 3).

The Data Requirement: "No JPEGs, Only Raw Data"

Chinese Grade 3A hospitals require precise data for Tumor Board approval. A standard clinic letter is insufficient. You must provide:

  • Pathology & Molecular: Original pathology report. Crucial: Raw flow cytometry files (.fcs format), not just the PDF summary. NGS panel results (if applicable) and IHC slides/blocks (to be shipped later if needed).
  • Imaging: Crucial: DICOM files on a CD/USB or via secure DICOM gateway. JPEGs of PET-CT scans are rejected by Chinese radiology departments.
  • Treatment History: Exact dates, doses, and responses for all prior lines of therapy. Crucial: Date of last chemotherapy/radiation. (This dictates the washout period required before cellular therapy).
Clinical Pearl

If the patient is being evaluated for CAR-T, ensure their most recent chemotherapy did not include prolonged high-dose corticosteroids or fludarabine, as these severely compromise T-cell fitness for apheresis.

2
DAYS 4-10

Handoff & Chinese Center Matching

Secure formal "Letter of Acceptance" from Chinese PI before patient books flight

Step 1: Secure Data Transfer

Documents are uploaded to our HIPAA/GDPR-compliant physician portal. We de-identify the data for initial review, ensuring compliance with international data privacy laws.

Step 2: The PI-to-PI Consultation

Within 48 hours, our Medical Directors present the case to the relevant Tumor Board at a partner Grade 3A hospital (e.g., Beijing Tiantan, Ruijin, or PUMCH).

  • Your Role: You are invited to join this virtual Tumor Board meeting via secure video link to present the case directly to the Chinese PI.
  • Outcome: The Chinese PI provides a preliminary clinical assessment and recommends a specific protocol (e.g., CD19 CAR-T, IL13Rα2 CAR-NK, or a specific Phase II trial).

Step 3: The Letter of Acceptance & Logistics

If accepted, the hospital issues a formal Letter of Acceptance and Treatment Plan. This document includes:

  • The exact NCT number (if a trial) or commercial protocol
  • Estimated dates for apheresis/collection and infusion
  • A transparent, line-item cost estimate (for self-pay patients)
  • The official invitation letter required for the Chinese Medical Visa (S2)
3
DAYS 11-21

Pre-Departure & Bridging Therapy

Keep patient alive and stable at home while awaiting travel and cell manufacturing

This is the most critical phase for the referring physician. The patient is at home, but the Chinese team is preparing for their arrival.

The Bridging Therapy Protocol: Do's and Don'ts

If the patient requires bridging therapy to control disease while awaiting cellular therapy, you must prescribe carefully to avoid ruining the future cellular product.

Bridging Scenario Recommended Approach Absolute Contraindications
Awaiting CAR-T (Autologous) Mild, non-lymphodepleting chemo (e.g., low-dose cyclophosphamide, bendamustine, or targeted agents like ibrutinib/venetoclax if applicable) Fludarabine, cladribine, or prolonged high-dose steroids (>10mg prednisone equivalent). These destroy the T-cells you need to collect.
Awaiting NK / Off-the-shelf CAR-T Since product is ready, bridging rarely needed. If required, use short-acting targeted therapy or palliative radiation Any therapy that causes severe neutropenia right before infusion date
Awaiting Clinical Trial Enrollment Standard palliative care or best supportive care (BSC) Experimental agents that might violate trial exclusion criteria (e.g., prior checkpoint inhibitors if trial forbids them)
Clinical Pearl

We mandate a "Bridging Therapy Check-in" 7 days before the patient's scheduled apheresis or travel date. You and our coordinator review the patient's CBC to ensure they are fit for collection.

4
DAYS 22-60

Active Treatment in China

Maintain absolute visibility into treatment and toxicity management without leaving your clinic

When the patient is in China, you should not experience a "communication black hole." Our protocol mandates the Weekly PI Update.

The Weekly PI Update Mechanism

Every Friday, the Chinese clinical research coordinator (CRC) sends a standardized Weekly Clinical Status Report directly to your email. This report includes:

  1. Current Day of Protocol: (e.g., "Day +7 post-CAR-T infusion")
  2. Toxicity Grading: Strictly graded using CTCAE v5.0. (e.g., "CRS Grade 2: Fever responsive to acetaminophen, no vasopressors required. ICANS Grade 0.")
  3. Interventions: Exact doses of Tocilizumab, corticosteroids, or antibiotics administered
  4. Laboratory Trends: Key metrics (ANC, Platelets, CRP, Ferritin, CAR-T expansion copies if available)
  5. PI Comments: A brief, plain-English note from the Chinese PI highlighting any concerns

Managing Severe Adverse Events (SAEs)

If a Grade 3+ SAE occurs, the protocol triggers an Immediate PI-to-PI Alert.

  • You will receive a phone call from our Medical Director within 2 hours of the event
  • You will be provided with the Chinese hospital's SAE management protocol (translated into English)
  • If necessary, we facilitate an emergency 3-way telemedicine call between you, the patient's companion, and the Chinese PI to align on the care plan
5
DAY 61+

Repatriation & Exit Report

Seamlessly reintegrate patient into your local care practice with comprehensive documentation

Chinese hospitals generate massive amounts of data, but it is often unstructured and in Chinese. We act as the clinical translator and data curator. Before the patient flies home, we compile the Standardized Exit Package.

Anatomy of the Standardized Exit Package

You will receive a single, beautifully formatted PDF dossier containing:

Clinical Discharge Summary

Written in medical English. Includes: Admission diagnosis, exact treatment administered (cell dose, viral titer, etc.), hospital course, and discharge condition.

Toxicity Log

Day-by-day table of all adverse events, graded per CTCAE v5.0, and exact management applied.

Manufacturing Report (For CAR-T)

Certificate of Analysis (CoA) from GMP lab: cell viability, CAR+ percentage, CD4/CD8 ratio, vector copy number.

Imaging & Pathology

Discharge PET-CT or MRI in DICOM format on USB (load directly into your PACS). Translated pathology reports.

Follow-Up Schedule

Chinese PI's exact recommendations for local monitoring (e.g., "CBC weekly × 4 weeks, PET-CT at Day 90, bone marrow biopsy at 6 months").

Management Instructions

Specific instructions on managing delayed cytopenias or hypogammaglobulinemia (e.g., IVIG replacement protocols).

The "Continuity of Care" Guarantee

To ensure you never feel disconnected from your patient's care, we operate under a strict PI-to-PI Communication Charter:

  1. You are the Primary Oncologist: We view ourselves as an extension of your practice, not a replacement. All major clinical decisions in China are made with your input.
  2. Direct Access: You are provided with the direct, personal WeChat/Email of the Chinese PI and our Medical Director. You do not have to go through a customer service desk.
  3. Post-Treatment Telemedicine: At Day 30 and Day 90 post-treatment, we schedule a mandatory 3-way telemedicine consult (You + Patient + Chinese PI) to review the response and adjust the long-term care plan.
  4. Relapse Management: If the patient relapses after returning home, the Chinese PI will provide a written recommendation for the next line of therapy, ensuring you have global expertise at your fingertips.

Downloadable Resources for Your Practice

To streamline this process, we have developed standardized templates for your clinic.

Standardized International Referral Form (SIRF)

2-page PDF template. Ensures all necessary data (ECOG, prior lines, exact last chemo date, biomarker status) is captured in format Chinese Tumor Boards prefer. Reduces back-and-forth emails by 80%.

PDF • Gated Download
Bridging Therapy Cheat Sheet

Quick-reference guide for clinic nurses and junior doctors on what medications are safe while patient awaits cellular therapy in China.

PDF • Gated Download
PI-to-PI Communication Charter

Formal document outlining communication protocols, response times, and data-sharing agreements between your clinic and partner hospitals in China.

PDF • Gated Download
Gated Downloads

To access these resources, please enter your Name, Medical License Number, Hospital, and Email. This builds a high-quality database of referring oncologists and ensures compliance with medical professional standards.

Ready to Initiate a Referral?

You have a patient who needs advanced cellular therapy or a clinical trial. You want the best science, but you refuse to compromise on continuity of care. Download the SIRF Template, attach DICOM imaging and raw flow cytometry files, and email to referrals@cancercaree.com. Within 48 hours, you will receive a preliminary Tumor Board assessment.

Enter Physician Referral Portal